SUNNYVALE, Calif., July 31, 2017 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today it has received 510(k)
clearance from the U.S. Food and Drug Administration (FDA) for its
iDMS™ Data Management System, enabling its use with the Company's
TomoTherapy® platform. It's designed to integrate with a wide range
of technologies, including the Radixact™, TomoTherapy® and
CyberKnife® Systems, Accuray Precision™ Treatment Planning System,
and third-party treatment planning and oncology information
systems.
The iDMS System is a centralized database that shares and makes
data accessible between multiple Accuray treatment delivery
systems, adding flexibility and improving efficiency in the
radiation therapy department. It provides an integrated platform
for storing and managing all patient and treatment plan data,
allowing clinicians to securely and seamlessly access the data they
need to drive efficient, informed, effective radiation
treatments.
"This most recent clearance reinforces Accuray's commitment to
providing clinicians with options for seamless, fully integrated
treatment planning and data management, enhancing department
workflow efficiency," said Lionel Hadjadjeba, Senior Vice
President, and Chief Commercial Officer at Accuray. "The common
database will make it possible for clinicians to use any available
Accuray treatment system, expanding patient access to the precision
and treatment versatility of our advanced radiation therapy
systems."
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company
that develops, manufactures, and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The Company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
market acceptance of our new technologies, and Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed from
time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's reports on Form 10-Q, filed on
November 1, 2016, February 3, 2017, and May
5, 2017, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jane Hauser
MSLGROUP
+1 (781) 684-0770
accuray@mslgroup.com
Investor Contact:
Doug Sherk
Investor Relations, EVC Group
+1 (415) 652-9100
dsherk@evcgroup.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/accuray-receives-510k-clearance-for-idms-data-management-system-upgrade-for-the-tomotherapy-system-300496265.html
SOURCE Accuray Incorporated